

basis for the genetic selection (duration of the loss of the righting reflex).

Our results indicate that a gene expression system can be used to define genetic differences in brain function. Expression studies in coordination with pharmacological genetic selection offer a promising strategy for the study of drug-receptor interactions.

REFERENCES AND NOTES

1. J. R. Wilson and R. Plomin, *Soc. Biol.* **32**, 162 (1986).
2. G. E. McClearn and R. Kakhana, *Behav. Genet.* **3**, 409 (1973).
3. E. J. Gallaher, L. E. Hollister, S. E. Gionet, J. C. Crabbe, *Psychopharmacology* **93**, 25 (1987); J. K. Belknap, N. R. Halmi, D. M. Goebel, M. Lame, *Behav. Genet.* **13**, 383 (1983).
4. A. M. Allan and R. A. Harris, *Life Sci.* **39**, 2005 (1986).
5. R. A. Harris and A. M. Allan, *Brain Res.* **490**, 26 (1989); *FASEB J.* **3**, 1689 (1989).
6. P. R. Schofield *et al.*, *Nature* **328**, 221 (1987); E. S. Levitan *et al.*, *ibid.* **335**, 76 (1988); D. B. Pritchett *et al.*, *ibid.* **338**, 582 (1989).
7. K. M. Houamed *et al.*, *ibid.* **310**, 318 (1984).
8. P. D. Suzdak, S. M. Paul, J. N. Crawley, *J. Pharmacol. Exp. Ther.* **245**, 880 (1988); A. M. Allan and R. A. Harris, in *Recent Developments in Alcoholism*, M. Galanter, Ed. (Plenum, New York, 1987), vol. 5, pp. 313–325.
9. A. M. Allan and R. A. Harris, *Pharmacol. Biochem. Behav.* **27**, 665 (1987); S. J. McQuilkin and R. A. Harris, *Life Sci.* **46**, 527 (1990); P. D. Suzdak, R. D. Schwartz, S. M. Paul, *Proc. Natl. Acad. Sci. U.S.A.* **83**, 4071 (1986); A. K. Mehta and M. K. Ticku, *J. Pharmacol. Exp. Ther.* **246**, 558 (1988).
10. D. P. Harris and J. G. Sinclair, *Gen. Pharmacol.* **15**, 449 (1984); J. R. Mancillas, G. R. Siggins, F. E. Bloom, *Science* **231**, 161 (1986); J. N. Nestoros, *ibid.* **209**, 708 (1980); J. J. Celentano, T. T. Gibbs, D. H. Farb, *Brain Res.* **455**, 337 (1989); R. Takada *et al.*, *Alcohol* **6**, 115 (1989); P. W. Gage and B. Robertson, *Br. J. Pharmacol.* **85**, 675 (1985).
11. LS and SS mice were obtained from the Institute for Behavioral Genetics (Boulder, CO). Polyadenylated RNA was prepared from whole brain pooled from four mice with a Fast Track isolation kit (Invitrogen, San Diego, CA). Polyadenylated RNA was isolated by oligo(dT) binding, further purified by phenol/chloroform extraction, and stored at -20°C . A total of six different mRNA preparations were made from LS and SS mice, with brains pooled from four randomly selected individuals for each preparation. Similar results were obtained with all preparations from each line of mice. Oocytes were prepared from adult female *Xenopus laevis* (Xenopus I, Ann Arbor, MI) as described (7, 12). The follicular cell layer was removed by a 10-min treatment in Sigma type 1A collagenase (0.5 mg/ml) dissolved in modified Barth's saline (MBS). Oocytes were injected with 50 nl of a solution of mRNA (2 to 4 mg/ml) with a 10- μl micropipette (Drummond Scientific, Broomall, PA) that had an internal diameter of 20 μm . Oocytes were then incubated for 2 to 3 days in MBS supplemented with 2 mM sodium pyruvate, penicillin (100 U/ml), streptomycin (100 mg/ml), gentamycin (50 mg/ml), and 0.5 mM theophylline. For electrophysiological recording, oocytes were placed on filter paper in a 200- μl bath and continually perfused with MBS, 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO_3 , 10 mM Hepes, 0.82 mM MgSO_4 , 0.33 mM $\text{Ca}(\text{NO}_3)_2$, 0.91 mM CaCl_2 , pH 7.3 to 7.5, at a rate of 1.7 ml/min. Cells were impaled with two microelectrodes (0.5 to 2 megohms) containing 3 M KCl and voltage-clamped with an Axoclamp IIA amplifier. We applied the perfused drugs by changing the saline solution to saline containing appropriate concentrations of drug. Wash-through time was ~ 5 s for total changeover of solution. We calculated drug concentrations by assuming complete equilibration; measured concentrations of ethanol at the time of peak response were about 40% less than the indicated concentrations.
12. K. A. Wafford, T. V. Dunwiddie, R. A. Harris, *Brain Res.* **505**, 215 (1989).
13. T. C. Howerton, M. F. O'Connor, A. C. Collins, *J. Pharmacol. Exp. Ther.* **227**, 389 (1983).
14. D. M. Lovinger, G. White, F. F. Weight, *Science* **243**, 1721 (1989); P. L. Hoffman, C. S. Rabe, F. Moses, B. J. Tabakoff, *J. Neurochem.* **52**, 1937 (1989). NMDA responses were studied in the absence of Mg^{2+} and in the presence of 3 μM glycine. A 100- μM concentration of NMDA was used to study ethanol action, and a 300- μM concentration was used to assess the maximal effect of NMDA.
15. M. K. Ticku and S. K. Kulkarni, *Pharmacol. Biochem. Behav.* **30**, 501 (1988); M. R. Palmer, C. van Horne, J. T. Harlan, R. A. Moore, *J. Pharmacol. Exp. Ther.* **247**, 1018 (1988); P. D. Suzdak *et al.*, *Science* **234**, 1243 (1986); R. A. Harris, A. M. Allan, L. C. Daniell, C. Nixon, *J. Pharmacol. Exp. Ther.* **247**, 1012 (1988).
16. W. J. Keir, R. A. Deitrich, J. M. Sikela, *Ann. N.Y. Acad. Sci.*, in press; N. R. Zahniser *et al.*, *Soc. Neurosci. Abstr.*, in press.
17. We thank J. Sikela for helpful discussions and assistance with mRNA techniques. Supported by the Veterans Administration and the National Institute of Alcoholism and Alcohol Abuse (AA06399 and AA03527).

27 December 1989; accepted 18 May 1990

MHC-Linked Protection from Diabetes Dissociated from Clonal Deletion of T Cells

JAN BÖHME, BRIGITTE SCHUHBAUR, OSAMI KANAGAWA, CHRISTOPHE BENOIST, DIANE MATHIS

The I-E molecule of the major histocompatibility complex (MHC) can prevent the spontaneous development of diabetes in nonobese diabetic (NOD) mice. The mechanism of this protection has been investigated by breeding wild-type and promoter-mutated E_{α} transgenes onto the NOD genetic background. Animals carrying the various mutated transgenes expressed I-E on different subsets of immunocompetent cells, and thus cells important for the I-E protective effect could be identified. Although the wild-type transgene prevented the infiltration of lymphocytes into pancreatic islets, none of the mutants did. However, all of the transgenes could mediate the intrathymic elimination of T cells bearing antigen receptors with variable regions that recognize I-E. Thus, the I-E molecule does not protect NOD mice from diabetes simply by inducing the deletion of self-reactive T cells.

THE NOD MOUSE PROVIDES A MODEL for studying the immunology of insulin-dependent diabetes mellitus (IDDM) in humans (1). The murine disease is similar to the human condition in several ways: (i) it is caused by specific T lymphocytes that invade and destroy the pancreatic islets (2–4); (ii) this can be alleviated or prevented by immunosuppressive reagents such as cyclosporin (5); and (iii) the disease, although under complex polygenic control, is influenced by a gene (or genes) in the major histocompatibility complex (MHC) (6–9).

The class II genes of the NOD MHC constitute a distinct haplotype: the I-A complex has a β chain of unusual sequence (10), and the I-E complex is absent because of a deletion in the α chain gene (7, 11). The importance of MHC class II genes, in particular of the defective E_{α} locus, has been demonstrated by introducing an E_{α} trans-

gene onto the NOD genetic background: this gene prevented lymphocyte infiltration into the pancreatic islets of 10-week-old mice (12). However, this result has not been accepted without question [see discussion in (8), for example]. Because only one transgenic line was used, the protection from insulinitis could have resulted from the chromosomal integration site of the transgene, from special features of the transgene construct, or from peculiarities of the E_{α} allele employed. Several hypotheses have been suggested to explain the protection phenomenon (4, 12). In one, diabetes in NOD mice was postulated to result from an autoimmune attack by T cells that carried the $V_{\beta}5$ variable region on their T cell antigen receptors (TCRs). Since T cells displaying $V_{\beta}5^{+}$ TCRs are negatively selected in the thymus of mice expressing the I-E molecule (13), the diabetogenic anti-islet clones would be deleted intrathymically when a wild-type E_{α} gene is introduced into NOD mice (4).

To verify the original observation and to assess where E_{α} must be expressed to protect from insulinitis, we have crossed the NOD strain with a number of E_{α} transgenic lines. One of them, $E_{\alpha}16$, expresses the I-E

J. Böhme, B. Schuhbaur, C. Benoist, D. Mathis, Laboratoire de Génétique Moléculaire des Eucaryotes du CNRS, Unité 184 de Biologie Moléculaire et de Génie Génétique de l'INSERM, Institut de Chimie Biologique, Faculté de Médecine, 67000 Strasbourg, France. O. Kanagawa, Department of Pathology, Washington University, School of Medicine, St. Louis, MO 63110.

complex on all cells that normally display class II molecules. In the other three lines, *Sma* 58, WED 21.16ΔX (ΔX), and WED 301.54ΔY (ΔY), expression is limited to particular compartments of the immune system (14, 15) (Fig. 1). Mice from each of the transgenic lines (carried on a C57BL/6 background) were mated with NOD mice to produce F₁ generations, which in turn were backcrossed with NOD mice (Fig. 2). This first backcross generation was doubly selected for the presence of the transgene and for homozygosity at the NOD MHC by evaluation of Southern blots of tail DNA. Several of the selected animals were again backcrossed with NOD mice to produce the experimental generation [N₃ according to standard nomenclature (16)]. N₃ females were evaluated for insulinitis at 10 to 12 weeks of age by examining pancreas sections (17) and, in parallel, were typed for the presence or absence of the transgene. By comparing *E*_α^{k+} and *E*_α^{k-} littermates in this manner, we evaluated the effect of the *E* molecule on insulinitis, independent of other segregating loci. (The ostensibly simpler approach of injecting the mutant transgenes directly into NOD embryos was not undertaken because the interesting "compartmentalized" expression patterns were obtained fortuitously; that is, they occurred in only one of many independent lines.)

Control animals lacking the transgene had an insulinitis incidence of about 40%, a value consistent with the hypothesis that as many as six loci from C57BL/6 mice dominantly

protect from diabetes (8), but at odds with another report (12). This complex genetic control was also manifest in the intensity of insulinitis exhibited by different animals. There was a distinct bimodal distribution: about one-fifth of the animals had more than 30% of their islets clearly infiltrated (as did all inbred NOD⁺ controls); the remaining four-fifths had fewer than 15% affected islets, and they were often only marginally infiltrated.

The wild-type *E*_α^k transgene from the *E*_α16 line bestowed almost complete protection from insulinitis (Fig. 1; *P* < 0.02). The only animal with any sign of T cell infiltration had fewer affected islets with only mild invasion. The protection was not due to a simple delay in the kinetics of autoimmune attack, as NOD/*E*_α16 mice remained insulinitis-free even at 6 months of age (11). The prevention of disease in NOD mice by an *E*_α^k transgene confirms the previous observation with an *E*_α^d transgene (12); together these data indicate that protection from insulinitis is due to the *E*_α gene itself, and is not an artifact of transgene insertion or linkage. Recent results with a NOD/*E*_α line generated by injecting an *E*_α^d gene directly into NOD embryos also confirmed this observation (18).

In contrast, none of the promoter-mutated transgenes significantly protected from insulinitis. The frequency and intensity of insulinitis was similar for N₃ backcross mice carrying the ΔX, ΔY, or *Sma* transgenes and for their transgene-negative littermates.

Since this result was rather surprising, we confirmed by microscopic analysis of the appropriate fluorescently labeled tissue sections that the mutant transgenes were expressed on the NOD background exactly as they are on the C57BL/6 background (11).

The ΔX, ΔY, and *Sma* transgenes can mediate the intrathymic deletion of I-E-reactive T cells, a fact demonstrated for a variety of TCR V_β regions (5, 6, 11, and 17a) on a variety of genetic backgrounds (for example, C57BL/6, SJL, and SJL × DBA/1) (11, 14). Thus, the lack of protection by these transgenes seems inconsistent with the hypothesis that I-E expression prevents insulinitis by eliminating V_β5⁺ T cells (4). To verify this point we stained peripheral lymphocytes from the NOD-backcrossed transgenic mice with an anti-V_β5 reagent and quantitated them by cytofluorimetry (Table 1). Three major points emerge. First, as in other strains (13), by far the majority of V_β5⁺ T cells in NOD mice occur in the CD8⁺ compartment. The reason for such a pronounced skewing is not yet known. Second, little I-E-mediated negative selection occurs on the NOD background: there is only moderate deletion of V_β5-bearing T cells in NOD/*E*_α16 transgenic mice, and essentially no deletion of T cells displaying V_β6 or V_β11. The extent of negative selection is influenced by background genes, in some cases *Mls* (19), and these loci seem not to be very conducive to negative selection in NOD mice. Third, all of the transgenes induced the same amount



	Thymus	Periphery	Repertoire selection		Insulinitis	
			Positive	Negative	Transgenics	Negative littermates
<i>E</i> _α 16		B : 100% + Mφ: +	+	+	1/18	10/26
ΔX		B : 100% + (heterogeneous) Mφ: +	-	+	11/33	14/24
ΔY		B : 20-50% + Mφ: -	+	+	12/21	17/31
<i>Sma</i>		B : 4% + Mφ: + (dull)	+	+	10/23	9/15

Fig. 1. *E*_α expression patterns and insulinitis frequency in NOD/*E*_α transgenic lines. The expression (first two columns) and repertoire selection data are essentially as described previously (14), but have been confirmed on the NOD background (11). Thymus expression is illustrated in the first column: normal *E*_α expression on epithelial cells of the cortex is shown as a reticulum in the outer oval, no expression as a blank outer oval; normal *E*_α expression on epithelial cells, dendritic cells, and macrophages in the medulla is indicated as a stippled inner oval, no expression as a blank inner oval. Insulinitis values denote the number of insulinitis-positive mice with respect to the total number of mice conclusively scored (17).




Fig. 2. Protocol for creation of the NOD/*E*_α lines. The NOD mice originated from a colony at the Department of Immunology, John P. Roberts Research Institute, London, Ontario, Canada. All of the females in our NOD colony develop insulinitis.

Table 1. T cell antigen receptor V_{β} usage in NOD/ E_{α} transgenic mice and E_{α} transgenics on SJL $\times$ DBA/1 and C57BL/6 genetic backgrounds. In individual mice, the percent of $CD4^{+}$ or $CD8^{+}$ cells that express a particular V_{β} is shown. TCR V_{β} usage was determined by cytofluorimetry (22). ND, not determined.

Trans-gene	NOD ($V_{\beta}5$)		SJL $\times$ DBA/1 ($V_{\beta}6$)	C57BL/6 ($V_{\beta}11$)
	$CD4^{+}$ *	$CD8^{+}$	$CD4^{+}$	$CD4^{+}$
None	0.6, 0.9, 0.7, 0.7, 0.6, 0.7	7.6, 7.8, 6.0, 8.1, 8.9, 7.6	4.0, 4.4, 2.9	5.2, 4.6, 4.0, 4.4
$E_{\alpha}16$	0.1, 0.2, 0.4, 0.2, 0.0, 0.3	3.0, 3.1, 2.4	0.5, 0.4	0.2, 0.5
ΔX	0.0, 0.2	3.7, 3.9, 2.7	0.4	0.7, 0.8, 1.0
ΔY	0.2, 0.2	4.2, 3.7	0.2	0.4, 0.7
<i>Sma</i>	0.2, 0.2, 0.4, 0.5	2.5, 1.3, 2.2	ND	ND

*The background has been subtracted.

of clonal deletion: the ΔX , ΔY , and *Sma* transgenes, which did not protect from insulinitis, eliminated $V_{\beta}5^{+}$ T cells similarly to the $E_{\alpha}16$ transgene, which did protect. Clonal deletion of other TCR V_{β} regions by the same set of transgenes was more extensive on a C57BL/6 or (SJL $\times$ DBA/1) genetic background.

Thus, our data are clearly inconsistent with the hypothesis that the I-E molecule protects NOD mice from insulinitis by mediating clonal deletion of $V_{\beta}5^{+}$ T cells. Other studies are also inconsistent: (i) none of the disease-provoking T cell clones isolated by other groups use $V_{\beta}5$, but instead, show rather heterogeneous V_{β} usage (20, 21); (ii) immunohistological studies of islets in young NOD mice show that the infiltrating T cells use diverse V_{β} regions (21); (iii) treatment of NOD mice with anti- $V_{\beta}5$ antibody does not eliminate disease (21).

More generally, our results argue against any I-E-mediated clonal deletion event as we currently understand it. The results cannot be explained simply by segregation of other loci (such as, T cell receptor, MIs, and insulinitis). We have scored E_{α}^{+} and E_{α}^{-} littermates, so with large numbers from multiple crossings, we should only be measuring the influence of E_{α} . It is also unlikely that an unknown, and hence untested, T cell receptor ($V_{\beta}x$) is differentially deleted in wild-type E_{α} as compared with ΔX , ΔY , and *Sma* transgenic mice. We have examined V_{β} deletions using all available anti- V_{β} reagents in mice of many different genetic backgrounds and never observed differential deletion. In addition, it would be rather amazing if ΔX , ΔY , and *Sma* transgenic mice, with their very different expression patterns, exhibited exactly the same defective elimination of a rare subpopulation.

Our data that none of the mutant transgenes prevent insulinitis may suggest another mechanism. Protection could require display of I-E on a certain type of cell and the *Sma*, ΔX , and ΔY transgenic mice might all

lack I-E expression on that particular cell [even though no such defect has been recognized in extensive analyses (14)]. Alternatively, protection could require display of the E molecule on two or more types of cells. Extensive complementation and adoptive transfer experiments need to be performed to distinguish between these possibilities. In the meantime, we note that the one functional defect common to the ΔX , ΔY , and *Sma* transgenic mice is an inability to prime I-E-restricted T cells in lymph node proliferation assays (14). The problem is different in each case: ΔX mice are not able to positively select I-E-restricted T cells; ΔY mice lack I-E molecules on their macrophages, which appear to be required for initiating a lymph node T cell response; and *Sma* transgenic mice lack I-E on B cells, which are the major presenting cells in the proliferative response (14, 15). So we are tempted to suggest that the protection mechanism involves a T cell proliferation response, not unlike the reaction to a foreign antigen. The I-E molecule would then have a positive influence rather than the negative one usually proposed.

REFERENCES AND NOTES

1. S. Tarui, Y. Tochino, K. Nonaka, Eds., *Insulinitis and Type 1 Diabetes: Lessons from the NOD Mouse* (Academic Press, Tokyo, 1986); L. Castano and G. S. Eisenbarth, *Annu. Rev. Immunol.* **8**, 647 (1990).
2. T. Fujita et al., *Biomed. Res.* **3**, 429 (1982); Y. Kanazawa et al., *Diabetologia* **27**, 113 (1984); M. Ogawa et al., *Biomed. Res.* **6**, 103 (1985); M. Dardenne, F. Lepault, A. Bendelac, J.-F. Bach, *Eur. J. Immunol.* **19**, 889 (1989); L. D. Wicker, B. J. Miller, Y. Mullen, *Diabetes* **35**, 855 (1986); A. Bendelac, C. Carnaud, C. Boitard, J.-F. Bach, *J. Exp. Med.* **166**, 823 (1987); B. J. Miller, M. C. Appel, J. J. O'Neil, L. S. Wicker, *J. Immunol.* **140**, 52 (1988); C. Boitard, A. Bendelac, M. F. Richard, C. Carnaud, J.-F. Bach, *Proc. Natl. Acad. Sci. U.S.A.* **85**, 9719 (1988); P. Bedossa, A. Bendelac, J.-F. Bach, C. Carnaud, *Eur. J. Immunol.* **19**, 1947 (1989); T. Koike et al., *Diabetes* **36**, 539 (1987); J. A. Shizuru, C. Taylor-Edwards, B. A. Banks, A. K. Gregory, C. G. Fathman, *Science* **240**, 659 (1988); A. R. Hayward and M. Shreiber, *J. Immunol.* **143**, 1555 (1989); R. A. Jackson, M. A. Morris, B. F. Haynes, G. S. Eisenbarth, *N. Engl. J. Med.* **306**,

- 785 (1982); G. F. Bottazzo, *ibid.* **313**, 353 (1985); A. K. Foulis, C. N. Liddle, M. A. Farquharson, J. A. Richmond, R. S. Wein, *Diabetologia* **29**, 267 (1986).
3. K. Haskins, M. Portas, B. Bradley, D. Wegmann, K. Lafferty, *Diabetes* **37**, 1444 (1988); K. Haskins, M. Portas, B. Bergman, K. Lafferty, B. Bradley, *Proc. Natl. Acad. Sci. U.S.A.* **86**, 8000 (1989).
4. E.-P. Reich, R. S. Sherwin, O. Kanagawa, C. A. Janeway, *Nature* **341**, 326 (1989).
5. Y. Mori et al., *Diabetologia* **29**, 244 (1986); C. R. Stiller et al., *N. Engl. J. Med.* **308**, 1226 (1983); C. R. Stiller et al., *Science* **223**, 1362 (1984); R. Assan et al., *Lancet* **i**, 67 (1985); G. Feutren et al., *ibid.* **i**, 119 (1986); P. F. Bougneres et al., *N. Engl. J. Med.* **318**, 663 (1988).
6. M. Prochazka, E. H. Leiter, D. V. Serreze, D. L. Coleman, *Science* **237**, 286 (1987); L. S. Wicker et al., *J. Exp. Med.* **165**, 1655 (1987); L. S. Wicker, B. J. Miller, P. A. Fischer, A. Pressey, L. B. Peterson, *J. Immunol.* **142**, 781 (1989); M. Prochazka, D. V. Serreze, S. M. Worthen, E. H. Leiter, *Diabetes* **38**, 11 (1989).
7. M. Hattori et al., *Science* **231**, 733 (1986).
8. E. H. Leiter, *FASEB J.* **3**, 2231 (1989).
9. J. A. Todd, J. I. Bell, H. O. McDavitt, *Nature* **329**, 599 (1987); J. A. Todd et al., *Science* **240**, 1003 (1988).
10. H. Acha-Orbea and H. O. McDavitt, *Proc. Natl. Acad. Sci. U.S.A.* **84**, 2435 (1987).
11. J. Böhme, C. Benoist, D. Mathis, unpublished results.
12. H. Nishimoto, H. Kikutani, K.-I. Yamamura, T. Kishimoto, *Nature* **328**, 432 (1987).
13. J. Bill, V. B. Apple, E. Palmer, *Proc. Natl. Acad. Sci. U.S.A.* **85**, 9184 (1988).
14. W. van Ewijk et al., *Cell* **53**, 357 (1988); W. van Ewijk, C. Benoist, D. Mathis, unpublished results.
15. M. Le Meur, P. Gerlinger, C. Benoist, D. Mathis, *Nature* **316**, 38 (1985); C. Benoist and D. Mathis, *Cell* **58**, 1035 (1989); *Semin. Immunol.* **1**, 117 (1989).
16. P. L. Altman and D. D. Katz, Eds., *Biological Handbooks: Inbred and Genetically Defined Strains of Laboratory Animals* (Federation of American Societies for Experimental Biology, Bethesda, MD, 1978).
17. Pancreata from 10- to 12-week-old animals were fixed in modified Bouin's solution [picric acid 36 g/liter, copper acetate 18 g/liter, 3.3% formaldehyde, and 0.9% acetic acid], embedded in paraffin blocks, and cut in a minimum of eight sections at least 200 μ m apart. The sections were stained with hematoxylin and eosin and examined by light microscopy by two different investigators, who had no knowledge of their genotypes. A mouse with two or more distinct islets having more than ten lymphocytes obviously inside the islet capsule was scored as positive. A mouse with 50 or more islets examined, none of which was clearly infiltrated, was scored as negative. Mice that after extensive screening did not fulfill either the positive or the negative criteria (in total four mice) were dropped from the study.
18. M. Uehira et al., *Int. Immunol.* **1**, 209 (1989).
19. J. W. Kappler, U. Staerz, J. White, P. C. Marrack, *Nature* **332**, 35 (1988); H. R. MacDonald et al., *ibid.* **332**, 40; A. M. Pullen, P. Marrack, J. W. Kappler, *ibid.* **335**, 796 (1988).
20. K. Haskins, personal communication.
21. H. Kikutani and T. Kishimoto, personal communication.
22. Inguinal lymph node cells were analyzed by three-color cytofluorimetry, staining with the monoclonal antibodies MR 9.4 for $V_{\beta}5$, 44.22.1 for $V_{\beta}6$, or RR 3.15 for $V_{\beta}11$ (red), α CD4 (orange) and α CD8 (green) according to C. Benoist and D. Mathis, *Cell* **58**, 1027 (1989).
23. We thank T. Kishimoto and H. Kikutani for helpful discussions; C. Janeway, K. Haskins, and M. MacDuffie for commenting on the manuscript; H. Gunn, J. Tucker, and C. Stiller for NOD breeding pairs; P. Gerber, P. Rosay, and G. Lang for technical assistance; and P. Sourinphoumy for maintaining the animal facility. Supported by institutional funds from the INSERM and the CNRS and by grants to D.M. and C.B. from the NIH (U.S.) and the Juvenile Diabetes Foundation. J.B. received a fellowship from the Juvenile Diabetes Foundation.

28 February 1990; accepted 11 June 1990